Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lithium SCHEMBL1842524 | 0.91 | MAPK1 (0.40) | PIK3CAABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1842521 | 0.91 | MAPK1 (0.40) | PIK3CAABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1842971 | 0.91 | ABL1 (0.43) | ABL1NPC1RAB9ASMN1; SMN2 | |
| Lithium Ion SCHEMBL1842522 | 0.90 | NPC1 (0.39) | ABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1841496 | 0.90 | ABL1 (0.43) | ABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2181540 | 0.88 | PIK3CA (0.40) | PIK3CAPIK3CGABL1 | |
| SCHEMBL1841659 | 0.87 | NPC1 (0.43) | ABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1841588 | 0.87 | — | — | |
| SCHEMBL1842433 | 0.87 | ABL1 (0.42) | PIK3CAPIK3CGABL1NPC1RAB9A | |
| SCHEMBL1844391 | 0.85 | ABL1 (0.40) | ABL1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166088-A1 | BENZOTHIAZOLES AND AZA-ANALOGUES THEREOF USE AS ANTIBACTERIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2011-07-07 | — | — | US | claimed |
| US-20110166088-A1 | BENZOTHIAZOLES AND AZA-ANALOGUES THEREOF USE AS ANTIBACTERIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2011-07-07 | — | — | US | disclosed |
| EP-2321309-A1 | BENZOTHIAZOLES AND AZA-ANALOGUES THEREOF USE AS ANTIBACTERIAL AGENTS | Ranbaxy Laboratories Limited (IN) | 2011-05-18 | — | — | EP | disclosed |
| WO-2009156966-A1 | BENZOTHIAZOLES AND AZA-ANALOGUES THEREOF USE AS ANTIBACTERIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166088-A1 | BENZOTHIAZOLES AND AZA-ANALOGUES THEREOF USE AS ANTIBACTERIAL AGENTS | TOP2B, TOP1, POLI | PIK3CA 212/4885PIK3CG 1077/4885ABL1 1206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.